Compare Crocs, Inc. (CROX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Revvity Inc — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.60B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3× Crocs, Inc.'s market cap, and Revvity Inc pays a 0.18% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Revvity Inc for 12 Days on average.
| CROX | RVTY | |
|---|---|---|
Market Cap | $5.60B | $16.98B |
Volume | 1,026,773 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $157.36 |
52-Week Low | $73.39 | $82.26 |
Typical Hold Time | 96 Days | 12 Days |
Enterprise Value | $7.12B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CROX trades at $115.20, down 4.18% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 10.23 and P/S of 1.46. Recent earnings beats and a 51% analyst buy rating support fundamental strength, but 2025 net income turned negative due to tax impacts. The stock faces resistance near $116-119 with support at $114.
Outlook remains mixed: strong brand positioning and earnings momentum contrast with technical weakness and recent profitability challenges. The consensus price target of $136.78 suggests 19% upside, but investors should weigh competitive pressures and consumer spending volatility against valuation appeal.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
